



### To reshape drug discovery for the benefit of patients



### SUPPORTING THE DRUG DISCOVERY INDUSTRY

SMEs and innovators to deliver growth for the drug discovery economy



# LEVERAGING UK INFRASTRUCTURE

Connecting the community



# TACKLING INDUSTRY-LED CHALLENGES

That limit today's discovery process




## INDUSTRIALISING AND DRIVING ADOPTION

Of new scientific tools and modern techniques for discovering medicines

# MDC capabilities

Biomarkers



Biomedical informatics



Target and pathway engagement





Drug Delivery Biodistribution





Cell model analysis and validation





Virtual R&D and Syndicates







### **MDC Informatics**

Analyse and interpret complex data to help you to make decisions about developing new medicines



Multidisciplinary expertise



In-house developed assets



Integration of third party data





Specialised software




Data infrastructure

### Team and expertise







### **Data Science**



Data Infrastructure

Data management, FAIR data, Software development, Workflows, Infrastructure services



Machine learning, Text mining, NLP, Image recognition, Computer vision

### Informatics capabilities

### assets

#### CartaPharma

Resource integrating ext & int data assets

#### **CrISPy**

DB with insights about drug discovery UK companies

#### Aurac

Plugin enriching and visualising biochem entities

#### **AssayNet**

Data mining resource of assays, drugs & targets

#### Ares

Virtual screening pipeline suing structural methods

#### DeepADMET

Data mining resource of ADMET properties

#### DREaM.ai

DB ranking drugs based on its properties

#### **Apollo**

DB of antimicrobials & their gold-standard annotations

#### MDC-PPDMS

Database of druggable domains

#### **DSP ATLAS**

Tool to manage & analyse spatial expression data

#### **DARTS**

DB of real drugs and biological targets

#### **Asclepius**

DB of Clinical Trials & Drug-Target-Disease annotations

#### **VESPA**

Tool to predict the impact of mutations in proteins

#### **Narcissus**

Tool to handle metadata & support analysis workflows

#### **Polyphemus**

DB with compounds from vendors and external DBs

#### Pan

Enriched library of chemical structures using FBLD

#### Dionysus

Dataset of drugged and druggable genes

#### DocLib

Software components for text mining


#### **NER**

Tool for named entity recognition for biochem

#### AMBER+

Toolkit to use and integrate AMBER

### capabilities



## insights

Disease mechanisms

**Biomarkers** 

**Targets** 

Druggability

Drugs


Efficacy



### Workshop expectations


Learn more about health data resources and solutions to access, integrate, and analyse health data

Explore the **opportunity** for public funded service providers to **work as a collective** to support SMEs






# Data to insights



### Data to insights



Artificial Intelligence in Drug Discovery & the UK Biotech Sector
Insights from the State of the Discovery Nation 2019

https://md.catapult.org.uk/wpcontent/uploads/2019/05/sodn19-aiinsights.pdf

**DATA** 


Provider

Use of health data by the life sciences industry

https://md.catapult.org.uk/wpcontent/uploads/2019/10/health-datareport.pdf


- No <u>capacity</u> to help SMEs with their technical requirements
- Limited number of tools and refence data to support data analysis
- Limited <u>data analysis support</u> or domain knowledge to help with data analysis


### Work as a collective



### Questions

- What are the <u>needs</u> (and bottlenecks) of SMEs to <u>exploit</u> cohort data?
- What practical <u>solutions</u> could be easily implemented <u>across</u> <u>organisations</u> to support SMEs?
- What <u>agreements</u> <u>between</u> <u>organisations</u> could help to better support SMEs?





### Follow up proposal

Work as a collective to support SMEs to get insights from health data

